Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
971 studies found for:    vincristine
Show Display Options
Rank Status Study
1 Completed Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Conditions: Soft Tissue Sarcoma;   Lymphoma;   Leukemia;   Wilms' Tumor;   Osteosarcoma
Intervention: Drug: Liposomal Vincristine
2 Unknown  Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
Condition: Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Vincristine Sulfate Liposome;   Drug: Vincristine Sulfate
3 Terminated
Has Results
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
Condition: Hemangioma
Interventions: Drug: Vincristine;   Drug: Prednisone
4 Completed To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Conditions: Sarcoma;   Neuroblastoma;   Wilms Tumor;   Leukemia;   Lymphoma;   Brain Tumors
Intervention: Drug: Marqibo
5 Recruiting A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
Conditions: Kaposiform Hemangioendothelioma (KHE);   Kasabach-Merritt Syndrome;   Tufted Angioma
Interventions: Drug: Vincristine;   Drug: Sirolimus
6 Recruiting Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Vincristine Sulfate Liposome;   Other: Laboratory Biomarker Analysis
7 Completed MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma;   Transformed Follicular Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Alisertib (MLN8237) + Rituximab + Vincristine
8 Completed Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma
Interventions: Drug: bryostatin 1;   Drug: vincristine sulfate
9 Completed
Has Results
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
Condition: Malignant Melanoma
Intervention: Drug: Vincristine Sulfate Liposomes Injection
10 Recruiting Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy
Condition: Vincristine Induced Peripheral Neuropathy (VIPN)
Interventions: Drug: Injection Mecobalamin,;   Drug: Tablet Pyridoxine hydrochloride;   Drug: Intravenous normal saline 1 ml;   Drug: Placebo pill
11 Completed Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Drug: bryostatin 1;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis
12 Withdrawn Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vincristine Sulfate Liposome;   Drug: Volasertib
13 Completed Bryostatin and Vincristine in B-Cell Malignancies
Conditions: Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bryostatin 1;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis
14 Completed
Has Results
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Marqibo® (vincristine sulfate liposomes injection)
15 Completed Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide
16 Completed
Has Results
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Vincristine Sulfate Liposomes Injection;   Drug: Dexamethasone
17 Active, not recruiting Vincristine PK and PD in the AYA Population Compared to Younger Children
Conditions: Leukemia, Acute Lymphoblastic;   Leukemia
Intervention:
18 Terminated A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Condition: Acute Lymphoblastic Leukemia (ALL)
Interventions: Drug: Vincristine Sulfate Liposomes Injection (VSLI);   Drug: Vincristine Sulfate Injection (VSI)
19 Terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Small Intestine Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: obatoclax mesylate;   Drug: liposomal vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Recruiting Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Conditions: ALL, Childhood;   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Leukemia, Acute
Intervention: Drug: Marqibo in combination with UK ALL R3

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.